Skip to main content
    A

    Anika Therapeutics Inc (ANIK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $12.85
    -0.07 (-0.54%)

    Market Cap: $173.07M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Anika Therapeutics Inc (ANIK) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Anika Therapeutics (ANIK) has a market cap of $173.07M and an enterprise value of $128.11M. Its share count is down 7.15% from a year earlier. It holds $44.96M more cash than debt, 25.98% of its market cap.

    Total Valuation

    Enterprise value is 25.98% below the market cap, as cash exceeds debt.

    Market Cap$173.07M
    Enterprise Value$128.11M
    Latest price (Nov 17, 2026)$12.85

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.44% in the quarter ended Sep 30, 2026 and shrank 4.79% a year over 2 years.

    Shares Outstanding13.39M
    Shares Change (YoY)-7.15%
    Shares Change (QoQ)+0.44%
    Share Count Growth (2Y CAGR)-4.79%

    Valuation Ratios

    Sales and book value multiples are 1.4x and 1.3x. Its year-end P/E ranged from 22.8x to 63.7x from 2016 to 2020.

    P/E Ratio18.6x
    Forward P/E359.9x
    P/S Ratio1.4x
    Forward P/S1.4x
    P/B Ratio1.3x
    P/TBV Ratio1.3x
    P/FCF Ratio75.0x
    P/OCF Ratio23.1x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 41.4x EBITDA and 55.4x free cash flow.

    EV / Sales1.0x
    EV / EBITDA41.4x
    EV / FCF55.4x

    Price Statistics

    The stock is up 28.63% over 52 weeks and trades 33.52% below its 50-day average.

    Beta (1Y)0.71
    52-Week Change+28.63%
    1-Month Change-36.45%
    3-Month Change-39.56%
    6-Month Change-13.29%
    5-Year Change-49.70%
    10-Year Change-52.77%
    Total Return (1Y)+28.63%
    Total Return (3Y CAGR)-15.10%
    Total Return (5Y CAGR)-20.55%
    Return vs SPY (1Y)+21.33%
    Max Drawdown (1Y)-41.67%
    Max Drawdown (3Y)-71.83%
    Sharpe Ratio (1Y)0.49
    Correlation with SPY (1Y)0.17
    50-Day Average$19.33
    200-Day Average$16.45
    52-Week Range$9.01 to $22.88
    RSI (14 Days)22.3
    Average Volume (20 Days)113.18K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.86x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.86x
    Quick Ratio2.72x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -1.28% over the last 12 months, against a 5-year average of -17.38%.

    Return on Equity (ROE)-1.28%
    Return on Assets (ROA)-0.93%
    ROE (5Y Average)-17.38%
    ROA (5Y Average)-13.43%
    ROIC (5Y Average)-1.49%
    Asset Turnover0.65x
    Inventory Turnover1.53x
    Receivables Turnover4.63x
    Cash Conversion Cycle267 days

    Scores

    ANIK has an Altman Z-Score of 3.51, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.51
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $123.43M over the last 12 months is up 9.42% from the 12 months before.

    Revenue$123.43M
    Revenue Growth (YoY)+9.42%
    Gross Profit$78.26M
    Operating Income-$2.60M
    Pretax Income-$999.00K
    Net Income-$1.77M
    EBITDA$3.07M
    Reported EPS (TTM)$0.69

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.56% of the $189.60M in total assets.

    Cash and Equivalents$44.96M
    Total Debt$0
    Net Cash$44.96M
    Net Cash Per Share$3.36
    Working Capital$76.32M
    Shareholder Equity$137.58M
    Book Value Per Share$10.28
    Tangible Book Value$128.15M
    Tangible Book Per Share$9.57
    Total Assets$189.60M
    Total Liabilities$52.02M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.19M of capital spending, operating cash flow left $2.29M of free cash flow.

    Operating Cash Flow$7.48M
    Capital Expenditures$5.19M
    Free Cash Flow$2.29M
    FCF Per Share$0.17
    Depreciation and Amortization$5.67M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2.11%, against a 5-year average of -1.67%.

    Gross Margin63.40%
    Operating Margin-2.11%
    Pretax Margin-0.81%
    Net Margin-1.43%
    EBITDA Margin2.49%
    FCF Margin1.86%
    Gross Margin (5Y Average)61.74%
    Operating Margin (5Y Average)-1.67%
    Net Margin (5Y Average)-27.07%

    Growth

    Revenue fell 0.30% a year over 3 years.

    Revenue Growth (3Y CAGR)-0.30%
    Revenue Growth (5Y CAGR)-2.86%
    FCF Growth (5Y CAGR)-17.53%
    Book Value Per Share Growth (2Y CAGR)-17.85%
    Tangible Book Per Share Growth (2Y CAGR)-18.71%

    Revenue and profit by year

    Dividends and Yields

    ANIK does not pay a dividend. Its free cash flow yield is 1.33%.

    Earnings Yield5.38%
    FCF Yield1.33%
    Buyback Yield8.61%
    Shareholder Yield8.61%

    Peer Position

    Against 9 similar companies, ANIK has the 5th highest P/S.

    P/S Ratio1.4x vs 0.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)+9.42% vs +13.08% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 5.98% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+5.98%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ANIK

    What is ANIK's market cap?

    Anika Therapeutics has a market cap of $173.07M. Its enterprise value, which adds debt and subtracts cash, is $128.11M.

    What is ANIK's P/E ratio?

    Anika Therapeutics has a trailing P/E ratio of 18.6x and a forward P/E of 359.9x.

    How many shares of ANIK are outstanding?

    Anika Therapeutics has 13.39M shares outstanding. The count is down 7.15% from a year earlier.

    Does ANIK pay a dividend?

    No. Anika Therapeutics does not pay a dividend.

    How much debt does ANIK have?

    Anika Therapeutics has $0 of total debt and $44.96M of cash and equivalents, a net cash position of $44.96M.